Vaxart (VXRT) reported topline 12-month safety results from the 400-participant sentinel safety cohort in its Phase 2b trial of an oral pill COVID-19 vaccine, comparing safety against an approved mRNA comparator. The news is limited to safety topline data, with no efficacy or numerical safety outcomes provided in the article.
Vaxart (VXRT) reported topline 12-month safety results from the 400-participant sentinel safety cohort in its Phase 2b trial of an oral pill COVID-19 vaccine, comparing safety against an approved mRNA comparator. The news is limited to safety topline data, with no efficacy or numerical safety outcomes provided in the article.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
